Business Wire

International WELL Building Institute Opens Enrollment for WELL Health-Safety Rating In Response to COVID-19 With Significant Early Adoption

8.7.2020 20:18:00 EEST | Business Wire | Press release

Share

The International WELL Building Institute (IWBI) announced that enrollment has opened today for the WELL Health-Safety Rating for Facility Operations and Management, with more than 100 organizations and real estate portfolios across the globe already enrolled. Organizations across a wide range of industries and geographic locations have responded swiftly to implement the program’s science-backed guidance as they seek to instill confidence and trust among their staff, stakeholders and the broader community.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200708005768/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The WELL Health-Safety Rating is an evidence-based, third-party verified rating for all new and existing building and space types focused on operational policies, maintenance protocols, emergency plans and stakeholder engagement strategies to help organizations prepare their spaces for re-entry in a post COVID-19 environment.

Adapted from features in the WELL Building Standard (WELL) that focus on facilities, maintenance and operations, the WELL Health-Safety Rating is designed to guide and empower the actions of large and small businesses alike in taking the necessary steps to prioritize the health and safety of their staff, visitors and stakeholders. It also serves as an annual process that supports efforts to promote the long-term health and safety of people.

“We’re all eager to get back to our workplaces, back to school, back to traveling, dining, and cheering on our favorite teams and performers,” said IWBI Chairman and CEO Rick Fedrizzi. “As organizations across the globe respond to the COVID-19 crisis through changes in policies and protocols, the WELL Health-Safety Rating delivers the evidence-based health strategies required to help them safely reopen with the confidence and integrity provided by third-party verification.”

Created by IWBI, the WELL Health-Safety Rating is informed by guidance developed by the World Health Organization (WHO), U.S. Centers for Disease Control and Prevention (CDC), global disease control and prevention centers and emergency management agencies, recognized standard-making bodies, such as ASTM International and ASHRAE, and leading academic and research institutions. IWBI has leveraged insights from its Task Force on COVID-19, established at the outset of the pandemic to help business and building leaders integrate actionable insights and proven strategies in the fight against COVID-19 and other respiratory infections.

“This moment has highlighted the critical role that buildings, and those that own and operate them, can play in supporting people’s health, safety and well-being,” said IWBI President Rachel Gutter. “This new rating aims to meet the urgent need to deliver high health and safety standards in all of the spaces we occupy. While longer term design strategies are important in reducing the risks of infectious disease spread, this rating focuses on strategies that can be implemented immediately to address acute threats, using our buildings and spaces as a first line of defense in the fight against COVID-19.”

Demonstrating thought leadership and commitment to the health and safety of their stakeholder communities, the following leading organizations are among the first that have enrolled to achieve the WELL Health-Safety Rating:

ACCIONA SA

Adventist Health

Aedifica

Alpin Limited (Masdar City)

American Savings Bank

Bartra Capital Property

CAMCO Management Co.

Carrier

Catalyst Partners

CBD Z03

CBRE Barcelona

CBRE Madrid

China Overseas Office Capital

Cleveland Clinic Courts / Cleveland Cavaliers

Climate Change Arena

Community Investment Strategies, Inc

CR Land

Deerns

Delos China

Delos Living LLC

Delta Electronics, Inc.

Denholtz Properties

Department of Earth System Science, Tsinghua University

Empire State Realty Trust

EMSI

GFP Real Estate

Ghelamco Poland Sp. z o.o.

Glenstar

GuocoLand China Ltd.

HBMSU

Heitman

Herman Miller Group

Hornets Sports & Entertainment - Spectrum Center

HRO

Infancix Co., Ltd

International Commerce Centre

International WELL Building Institute PBC

Ivanhoé Cambridge

Jiahui Health

JLL

Karisma Hotels and Resorts

Kilroy Realty Corporation

Kimball

Laguna

Lendlease Australia Office Portfolios: Australian Prime Property Fund Commercial, Lendlease International Towers Sydney Trust and Lendlease One International Towers Sydney Trust

Lincoln Property Company

M Moser Associates

Mace

Maple Leaf Sports & Entertainment (MLSE), which encompasses the Toronto Maple Leafs (NHL), Toronto Raptors (NBA), Toronto FC (MLS), & Toronto Argonauts (CFL)

Menarco Development Corporation

Milliken & Company

ML7

Montage International

Moody Center
National University of Singapore

New Belmont Arena

New York Yankees

Oak View Group

Out of the Box Ventures

Overbury Morgan Lovell

OVG Arena Alliance & Stadium Alliance

OVG Facilities

Pacers Sports & Entertainment: Bankers Life Fieldhouse (Indianapolis, Ind.)

Pacers Sports & Entertainment: St. Vincent Center/Indiana Pacers Training Facility (Indianapolis, Ind.)

Parmenter Realty Partners

Phipps Conservatory and Botanical Gardens

RMZ Corp

Rocket Mortgage FieldHouse / Cleveland Cavaliers & Cleveland Monsters

Royal Albert Hall

Rubrik India Pvt Ltd

Savanna

Serpentini Auto Group

Shanghai Landleaf Architecture Technology Co. Ltd

ShouGang Group

Sino-Ocean

Space Matrix Design Consultants Pvt. Ltd
Spurs Sports & Entertainment

TAIPEI 101 Tower

Taiwan Architecture & Building Center

Teknion

The Florida Panthers and BB&T Center

The Forestias

The Related Group

Thornton Tomasetti

TITANIUM OFFICE SOLUTIONS MEXICO

Uber Technologies, Inc.

UltraStar Harrah’s Ak Chin Resort Maricopa, Az.

United Center

Webster Bank Arena

Wells Fargo Center, Philadelphia, Pa.

Wolfgang Puck Fine Dining Group

Woonerf Inc.

Yuexiu Commercial

Upon achieving the designation, IWBI will issue the building or space a WELL Health-Safety seal.

The WELL Health-Safety Rating draws on principles established by IWBI’s WELL Building Standard, the premier standard for healthy real estate, which has surpassed 590 million square feet in registrations across 62 countries since inception. The WELL Building movement has been further amplified by over 12,000 WELL Accredited Professionals (APs) and registrants across the globe.

To learn more about the WELL Health-Safety Rating and to enroll, please visit www.wellcertified.com/health-safety.

About the International WELL Building Institute

The International WELL Building Institute (IWBI) is leading the global movement to transform our buildings, communities and organizations in ways that help people thrive. The WELL v2 pilot is the latest version of its popular WELL Building Standard (WELL), and the WELL Community Standard pilot is a district scale rating system that sets a new global benchmark for healthy communities. WELL is focused exclusively on the ways that buildings and communities, and everything in them, can improve our comfort, drive better choices, and generally enhance, not compromise, our health and wellness. IWBI mobilizes the wellness community through management of the WELL AP credential, the pursuit of applicable research, the development of educational resources, and advocacy for policies that promote health and wellness everywhere. IWBI is a participant of the United Nations Global Compact, the world’s largest corporate citizenship initiative, and helps companies advance the UN Sustainable Development Goals (SDGs) through the use of WELL. More information on WELL can be found here.

International WELL Building Institute, IWBI, the WELL Building Standard, WELL v2, WELL Certified, WELL AP, WELL, WELL Portfolio, The WELL Conference, the WELL Community Standard, WELL Health-Safety Rating and others, and their related logos are trademarks or certification marks of International WELL Building Institute pbc in the United States and other countries.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Judith Webb
media@wellcertified.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye